雷迪帕韦杂质
|
|
|
- CAS号:
- 1499193-65-5
- 英文名:
- (1R,3S,4S)-tert-butyl 3-(6-(7-(2-((S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-iMidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]iMidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate
- 英文别名:
- Ledipasvir IMP;Ledipasvir Impurity;ledipasvir Impurity C;(1R,3S,4S)-tert-butyl 3-(6-(7-(2-((S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-iMidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]iMidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carbox;tert-butyl (S)-6-(5-(7-(2-((1R,3S,4S)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazol-6-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro[2.4]heptane-5-carboxylate;(1R,3S,4S)-tert-butyl3-(6-(7-(2-((S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-iMidazol-Chemicalbook5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]iMidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate;5-Azaspiro[2.4]heptane-5-carboxylic acid, 6-[5-[7-[2-[(1R,3S,4S)-2-[(1,1-dimethylethoxy)carbonyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9,9-difluoro-9H-fluoren-2-yl]-1H-imidazol-2-yl]-, 1,1-dimethylethyl ester, (6S)-
- 中文名:
- 雷迪帕韦杂质
- 中文别名:
- 来迪派韦杂质4;雷迪帕韦杂质C;雷迪帕韦杂质杂质;雷迪帕韦杂质杂质(7个);(6S)-6-[5-[7-[2-[(1R,3S,4S)-2-[(1,1-二甲基乙氧基)羰基]-2-氮杂双环[2.2.1]庚烷-3-基]-1H-苯并咪唑-6-基]-9,9-二氟-9H-芴-2-基]-1H-咪唑-2-基]-5-氮杂螺[2.4]庚烷-5-甲酸叔丁酯
- CBNumber:
- CB52727573
- 分子式:
- C45H48F2N6O4
- 分子量:
- 774.9
- MOL File:
- 1499193-65-5.mol
|
|
|
雷迪帕韦杂质化学性质
-
密度:
-
1.40±0.1 g/cm3(Predicted)
-
|
-
酸度系数(pKa):
-
11.20±0.10(Predicted)
-
|
雷迪帕韦杂质性质、用途与生产工艺
景及概述[1] 雷迪帕维，英文名：Ledipasvir。雷迪帕维是吉利德抗丙肝重磅产品Harvoni的复方组合的成分之一，NS5A抑制剂抑制剂。Harvoni是美国吉利德研制的抗HCV药物，是第一个批准用于治疗基因1型丙肝感染，且不需要联合干扰素或利巴韦林的全口服抗丙肝方案。Harvoni既可以单药使用，也可以和其它口服制剂比如利巴韦林联合使用。Harvoni获得FDA“优先评审”资格，也是第7个获得“突破性药物”资质的药物。雷迪帕韦合成过程中会产生雷迪帕韦杂质，影响雷迪帕韦质量。
雷迪帕韦杂质
上下游产品信息
上游原料
下游产品
1499193-65-5, 雷迪帕韦杂质 相关搜索:
- 抗感染
- C45H48F2N6O4
- (6S)-6-[5-[7-[2-[(1R,3S,4S)-2-[(1,1-二甲基乙氧基)羰基]-2-氮杂双环[2.2.1]庚烷-3-基]-1H-苯并咪唑-6-基]-9,9-二氟-9H-芴-2-基]-1H-咪唑-2-基]-5-氮杂螺[2.4]庚烷-5-甲酸叔丁酯
- 来迪派韦杂质4
- 雷迪帕韦杂质C
- 雷迪帕韦杂质杂质
- 雷迪帕韦杂质杂质(7个)
- 1499193-65-5
- tert-butyl (S)-6-(5-(7-(2-((1R,3S,4S)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazol-6-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro[2.4]heptane-5-carboxylate
- (1R,3S,4S)-tert-butyl3-(6-(7-(2-((S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-iMidazol-Chemicalbook5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]iMidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate
- 5-Azaspiro[2.4]heptane-5-carboxylic acid, 6-[5-[7-[2-[(1R,3S,4S)-2-[(1,1-dimethylethoxy)carbonyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9,9-difluoro-9H-fluoren-2-yl]-1H-imidazol-2-yl]-, 1,1-dimethylethyl ester, (6S)-
- ledipasvir Impurity C
- Ledipasvir Impurity
- (1R,3S,4S)-tert-butyl 3-(6-(7-(2-((S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-iMidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]iMidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carbox
- Ledipasvir IMP